Shionogi & Co., a Japan-based pharmaceutical company, plans to acquire Sciele Pharma for $1.1 billion. The planned bid is aimed at expanding Shionogi’s sales network into the U.S. “As we have moved ahead on improving our product pipeline, we have been faced with increasingly imminent challenge of getting a hold of a sales network in the world’s largest market,” Shionogi president, Isao Teshirogi, said. Mr. Teshirogi added that Sciele should also help the company gain ...